Fund HoldingsLynx1 Capital Management LP

Total Portfolio Value
$346.17M
Total Bought
$52.18M
Total Sold
$3.47M
Net Transaction
+$48.71M
Filing Period:
Securities
SharesValue ($K)
Q1 2025
Q2 2025
Change
Q1 2025
Q2 2025
Weight (%)
Change
STOKE THERAPEUTICS INC(STOK)5,291,9295,404,674+112,74535,19161,34317.72%+26,152
MERUS N V1,568,8411,568,841066,03382,52123.84%+16,489
GH RESEARCH PLC(GHRS)6,443,9406,746,951+303,01171,07782,24523.76%+11,169
CULLINAN THERAPEUTICS INC(CGEM)3,215,7224,400,842+1,185,12024,34333,1389.57%+8,795
PROTAGONIST THERAPEUTICS INC733,014733,014035,44940,51411.70%+5,065
TSCAN THERAPEUTICS INC5,357,3477,857,347+2,500,0007,39311,3933.29%+4,000
IBIO INC01,538,573+1,538,57301,1740.34%+1,174
UPSTREAM BIO INC219,247219,24701,3422,4070.70%+1,066
PRECISION BIOSCIENCES INC766,0511,036,051+270,0003,6544,3511.26%+697
PASSAGE BIO INC9,256,9539,256,95303,2693,7061.07%+437
ASSEMBLY BIOSCIENCES INC010,366+10,36601880.05%+188
NEUPHORIA THERAPEUTICS INC45,80645,80602643250.09%+61
DESIGN THERAPEUTICS INC65,95465,95402552220.06%-32
C4 THERAPEUTICS INC7,098,1337,098,133011,35710,1502.93%-1,207
IBIO INC862,2790-862,2793,4660-3,466
ALLOGENE THERAPEUTICS INC11,057,00911,057,009016,14312,4943.61%-3,649
Page 1 of 1